• DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens.
  • BARDA*  coordinates the United States Government's efforts to assess, prevent, protect against, respond to, and recover from biological incidents.
  • DEINOVE will present the progress of its drug candidate's various programs at the Lightning Talks at the BARDA annual conference.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has been selected to present its first-in-class antibiotic candidate DNV3837/DNV3681 at BARDA Industry Day 2019, in Washington DC on October 16.

The BARDA Industry Day is the annual event dedicated to biological risk, whether of natural origin, accidental or intentional. At this congress, the BARDA presents the U.S. Government medical countermeasure priorities, and updates on the actions taken and the results obtained. The Lightning Talks, organized during this congress, are companies and research organizations pitching on medical innovations that can contribute to the protection against biological risks.

DEINOVE is one of the very few European companies selected for the Lightning Talks and will discuss about "DNV3837/DNV3681, a novel class of quinolonyl-oxazolidinone antibacterials targeting both urgent threats to public health and bioterrorism pathogens."

"We are very proud to have been selected for this event. The selection process is drastic, and we are one of the few non-American companies pitching at the Lightning Talks this year. The two potential applications of DNV3837/DNV3681 are of interest to the audience of high-level scientists, military and industry specialists, as well as funding agencies. This is a great opportunity to provide visibility to our antibiotic candidate," says Georges GAUDRIAULT, Scientific Director of DEINOVE.

DNV3837, the prodrug** of the DNV3681 molecule, is a narrow spectrum synthetic antibiotic, which specifically targets Gram positive bacteria. It is currently being tested as intravenous treatment of moderate to severe Clostridioides difficile infections, a real therapeutic need. It also demonstrated "exceptional activity" in an in vitro evaluation conducted by USAMRIID*** against Bacillus anthracis, a pathogen classified as "high priority" bioterrorist threat.


* Biomedical Advanced Research and Development Authority

** Prodrug: substance whose transformation in the body results in an active product

*** USAMRIID (United States Army Medical Research Institute of Infectious Diseases) is the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare.